clinical trial · NCT07745504
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Novo Nordisk A/S·phase3·not yet recruiting·n = 285
OverweightObesityCagrilintidePlacebo cagrilintidePlacebo semaglutide
brief summary
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
started
Aug 4, 2026
primary completion
May 18, 2027
completion
Jul 6, 2027
last updated
Aug 4, 2026
official title
A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol